Most Read Articles
Dr Margaret Shi, 13 Jul 2020

An MRI-first diagnostic pathway, combined with risk-tailored screening, is shown to improve the benefit-to-harm profile and cost-effectiveness of screening for prostate cancer (PCa), according to results of a recent lifetable modelling study presented at AACR 2020 Virtual Meeting II.

Christina Lau, 14 Jul 2020

Flat-dose nivolumab, administered as a 30-minute infusion, is well tolerated and active in Asian patients with previously treated advanced non-small-cell lung cancer (NSCLC), according to results of the phase IIIb CheckMate 870 study.

Natalia Reoutova, 17 Jul 2020

At a median follow-up of 22.9 months, atezolizumab plus carboplatin and etoposide (CP/ET), given as a first-line treatment, continued to demonstrate an improvement in overall survival (OS) vs placebo plus CP/ET in patients with extensive-stage small-cell lung cancer (ES-SCLC), according to updated results of the IMpower133 trial presented at the American Association for cancer Research (AACR) 2020 Virtual Annual Meeting II.

13 Feb 2020
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.

Estimating kidney function does the job in patients on cisplatin

25 Jul 2020

In patients receiving cisplatin-based chemotherapy, estimated glomerular filtration rate (eGFR) is sufficient for the determination of kidney function, a recent study has shown.

The study included 121 patients (median age, 55 years; 27 percent female), from which kidney function data over 470 cisplatin cycles were collected. Paired eGFR and urinary creatinine clearance (uCrCl) measurements were obtained. The primary outcome of interest was the number of false negatives, defined as cycles with uCrCl <50 mL/min/1.73 m2 but eGFR ≥50 mL/min/1.73 m2.

The median eGFR and uCrCl values before initiation of cisplatin treatment were 94 and 102 mL/min/1.73 m2, respectively.

Eight out of the 470 cycles saw false negatives, yielding a final rate of 1.7 percent (95 percent confidence interval [CI], 0.5–2.9; p=0.004). In all eight instances of false negatives, the uCrCl was lower than the eGFR (mean, 43 v 112 mL/min/1.73 m2; mean difference, 65 mL/min/1.73 m2; p<0.0001). Notably, none of the eight false negatives led to a delay in chemotherapy.

Linear mixed models showed that overall, uCrCl measurements were significantly higher than eGFR estimates (mean difference, 13.0 mL/min/1.73 m2; p<0.0001). Both measures were in adequate agreement in most cases, though researchers still documented outlying uCrCl values. The resulting overall agreement was thus relatively low, with an intraclass coefficient of 0.72.

Nevertheless, the researchers said that using eGFR as a strategy to measure kidney function (and omitting direct GFR measurement using uCrCl) is acceptable in patients with solid cancers receiving cisplatin chemotherapy.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Dr Margaret Shi, 13 Jul 2020

An MRI-first diagnostic pathway, combined with risk-tailored screening, is shown to improve the benefit-to-harm profile and cost-effectiveness of screening for prostate cancer (PCa), according to results of a recent lifetable modelling study presented at AACR 2020 Virtual Meeting II.

Christina Lau, 14 Jul 2020

Flat-dose nivolumab, administered as a 30-minute infusion, is well tolerated and active in Asian patients with previously treated advanced non-small-cell lung cancer (NSCLC), according to results of the phase IIIb CheckMate 870 study.

Natalia Reoutova, 17 Jul 2020

At a median follow-up of 22.9 months, atezolizumab plus carboplatin and etoposide (CP/ET), given as a first-line treatment, continued to demonstrate an improvement in overall survival (OS) vs placebo plus CP/ET in patients with extensive-stage small-cell lung cancer (ES-SCLC), according to updated results of the IMpower133 trial presented at the American Association for cancer Research (AACR) 2020 Virtual Annual Meeting II.

13 Feb 2020
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.